DBV Technologies (DBVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $692.19M
Last updated: Nov 17, 2026 at 11:03 AM ET
DBV Technologies (DBVT) Competitors
The companies most similar to DBV Technologies are Vir Biotechnology (VIR), 4D Molecular Therapeutics (FDMT) and Valneva SE ADR (VALN). By market cap, DBV Technologies ranks 10th of the 13 companies on this page; Vir Biotechnology (VIR) is the largest at $1.71B.
Peer Comparison
DBVT's ROIC of -130.3% is below the peer median of -45.3%, and its revenue growth of -42.9% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| 4D Molecular Therapeutics Inc (FDMT) | $689.52M | N/A | 8.5x | -208.6% | -46.4% | 4506.0% | 0.00% |
| Valneva SE ADR (VALN) | $538.42M | N/A | 3.2x | -110.3% | -44.2% | -27.7% | 0.00% |
| CureVac NV (CVAC) | $1.05B | N/A | 1.8x | 182.1% | N/A | -89.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immatics NV (IMTX) | $972.99M | N/A | 17.7x | 0.0% | N/A | 33.5% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Solid Biosciences LLC (SLDB) | $763.42M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Vor Biopharma Inc (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Inventiva Sa (IVA) | $879.90M | N/A | 133.4x | 0.0% | -327.7% | -76.7% | 0.00% |
| Peer median | $882.04M | 95.1x | 8.4x | 0.0% | -45.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to DBV Technologies, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| 4D Molecular Therapeutics Inc (FDMT) | 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. | FDMT competitors |
| Valneva SE ADR (VALN) | Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet... | VALN competitors |
| CureVac NV (CVAC) | CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). | |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Immatics NV (IMTX) | Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies... | IMTX competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Solid Biosciences LLC (SLDB) | Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States. | SLDB competitors |
| Vor Biopharma Inc (VOR) | Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. | VOR competitors |
| Inventiva Sa (IVA) | Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic... |
Frequently Asked Questions About DBVT
Who are DBV Technologies' main competitors?
The companies most similar to DBV Technologies include Vir Biotechnology (VIR), 4D Molecular Therapeutics (FDMT), Valneva SE ADR (VALN), CureVac NV (CVAC) and Nuvectis Pharma (NVCT), listed from the closest match.
Who is DBV Technologies' biggest competitor?
Vir Biotechnology (VIR) is both the largest of the similar companies at $1.71B and the closest match by business profile, size, sector and industry.
How does DBVT stock compare with its competitors?
DBVT's net margin is 0.0% against a peer median of 0.0%.
Which of DBV Technologies' competitors pays a higher dividend?
DBV Technologies pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is DBV Technologies bigger than its competitors?
No. DBV Technologies is 10th by market cap among the 13 companies on this page; the largest is Vir Biotechnology (VIR) at $1.71B.
DBVT pages: Overview, Financials, Competitors